Biểu đồ giá cổ phiếu NRXP
NRXP Thu nhập
NRX Pharmaceuticals Inc
$3.06
0.32%
$0.01
Tính đến ngày hôm nay:Aug 05, 15:33:18 GMT-4
Quay lại
NRX Pharmaceuticals Inc (NRXP) Thu nhập
Kết quả Lợi nhuận Mới nhất: Q1 '26
Được báo cáo: 2026-05-15
Lợi nhuận Lịch sử
Hàng quý
Hàng năm
EPS
Doanh thu
Earnings FAQ
NRXPの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
NRX Pharmaceuticals Inc NRXPの前四半期の収益はどうでしたか？
NRX Pharmaceuticals Incの収益見積もりはいくらですか？
NRX Pharmaceuticals Incの収益品質スコアはどれくらいですか？
NRX Pharmaceuticals Incはいつ収益を報告しますか？
NRX Pharmaceuticals Incの予想収益はいくらですか？
NRX Pharmaceuticals Incは収益予想を上回りましたか？
Thống kê chính
Giá đóng cửa trước
$3.05
Giá mở cửa
$3.02
Phạm vi ngày
$2.9 - $3.11
Phạm vi 52 tuần
$1.62 - $5.05
Khối lượng
556.5K
Khối lượng trung bình
1.1M
Tỷ suất cổ tức
--
EPS (TTM)
-1.28
Vốn hóa thị trường
$110.8M
NRXP là gì?
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
